Diligence memo · auto-generated · as of July 2, 2026
Celerpurus Inc
Celerpurus Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Celerpurus Inc operates in Biotechnology, based in DURHAM.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Celerpurus Inc has raised $525K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $375K on 2021-04-08.
Most recent recorded round closed around 2022-01-07.
Valuation (modeled)modeled
Provath models Celerpurus Inc at approximately $3.2M (range $80K–$23M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 4.5 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.5× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 12% of Biotechnology peers (4293 compared).
Modeled value ranks above 7% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., TAUC3 Biologics Ltd.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.